{"id":"https://openalex.org/W2947996306","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.1044","title":"Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study.","display_name":"Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study.","publication_year":2019,"publication_date":"2019-05-20","ids":{"openalex":"https://openalex.org/W2947996306","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.1044","mag":"2947996306"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2019.37.15_suppl.1044","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.1044","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2019.37.15_suppl.1044","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5058784740","display_name":"Sami Diab","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210134151","display_name":"University of Colorado Cancer Center","ror":"https://ror.org/04cqn7d42","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210134151"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sami Diab","raw_affiliation_strings":["University of Colorado Cancer Center, Aurora, CO;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Colorado Cancer Center, Aurora, CO;","institution_ids":["https://openalex.org/I4210134151"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090188675","display_name":"Hope S. Rugo","orcid":"https://orcid.org/0000-0001-6710-4814","observed_orcids":["https://orcid.org/0000-0001-6710-4814"]},"institutions":[{"id":"https://openalex.org/I4210167126","display_name":"UCSF Helen Diller Family Comprehensive Cancer Center","ror":"https://ror.org/05yndxy10","country_code":"US","type":"facility","lineage":["https://openalex.org/I180670191","https://openalex.org/I4210110664","https://openalex.org/I4210167126"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hope S. Rugo","raw_affiliation_strings":["UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA;","institution_ids":["https://openalex.org/I4210167126"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070265480","display_name":"Lida A. Mina","orcid":"https://orcid.org/0000-0003-2606-9922","observed_orcids":["https://orcid.org/0000-0003-2606-9922"]},"institutions":[{"id":"https://openalex.org/I2802412784","display_name":"Banner Health","ror":"https://ror.org/039wwwz66","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2802412784"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lida A. Mina","raw_affiliation_strings":["Banner Health, Phoenix, AZ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Banner Health, Phoenix, AZ;","institution_ids":["https://openalex.org/I2802412784"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113169602","display_name":"Shannon Puhalla","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]},{"id":"https://openalex.org/I4210134769","display_name":"University of Pittsburgh Medical Center","ror":"https://ror.org/04ehecz88","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210098814","https://openalex.org/I4210134769"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shannon Puhalla","raw_affiliation_strings":["University of Pittsburgh Medical Center Cancer Centers, Pittsburgh, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pittsburgh Medical Center Cancer Centers, Pittsburgh, PA;","institution_ids":["https://openalex.org/I4210128526","https://openalex.org/I4210134769"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000862048","display_name":"Reshma L Mahtani","orcid":"https://orcid.org/0000-0002-7711-8627","observed_orcids":["https://orcid.org/0000-0002-7711-8627"]},"institutions":[{"id":"https://openalex.org/I4210157065","display_name":"Sylvester Comprehensive Cancer Center","ror":"https://ror.org/0552r4b12","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I145608581","https://openalex.org/I4210101935","https://openalex.org/I4210157065"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Reshma L. Mahtani","raw_affiliation_strings":["Sylvester Cancer Center, Deerfield Beach, FL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sylvester Cancer Center, Deerfield Beach, FL;","institution_ids":["https://openalex.org/I4210157065"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075355393","display_name":"Norah Lynn Henry","orcid":"https://orcid.org/0000-0002-4771-5930","observed_orcids":["https://orcid.org/0000-0002-4771-5930"]},"institutions":[{"id":"https://openalex.org/I2801159745","display_name":"Huntsman Cancer Institute","ror":"https://ror.org/03v7tx966","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801159745","https://openalex.org/I4210148268"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Norah Lynn Henry","raw_affiliation_strings":["Huntsman Cancer Institute, Salt Lake City, UT;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Huntsman Cancer Institute, Salt Lake City, UT;","institution_ids":["https://openalex.org/I2801159745"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088946926","display_name":"Neelima Denduluri","orcid":"https://orcid.org/0000-0002-6075-6809","observed_orcids":["https://orcid.org/0000-0002-6075-6809"]},"institutions":[{"id":"https://openalex.org/I4210122908","display_name":"Virginia Cancer Specialists","ror":"https://ror.org/03tbabt10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210122908"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Neelima Denduluri","raw_affiliation_strings":["Virginia Cancer Specialists, Arlington, VA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Virginia Cancer Specialists, Arlington, VA;","institution_ids":["https://openalex.org/I4210122908"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022422153","display_name":"Denise Aysel Yardley","orcid":"https://orcid.org/0000-0002-8664-3458","observed_orcids":["https://orcid.org/0000-0002-8664-3458","https://orcid.org/0009-0008-1720-6183"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Denise A. Yardley","raw_affiliation_strings":["Sarah Cannon Rsrch Inst, Nashville, TN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Rsrch Inst, Nashville, TN;","institution_ids":["https://openalex.org/I4210100810"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100319015","display_name":"Yao Wang","orcid":"https://orcid.org/0000-0002-9352-422X","observed_orcids":["https://orcid.org/0000-0002-9352-422X"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yao Wang","raw_affiliation_strings":["Pfizer Inc., New York, NY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc., New York, NY;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082478472","display_name":"Lillian Shahied Arruda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lillian Shahied Arruda","raw_affiliation_strings":["Pfizer Inc, San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc, San Francisco, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048191133","display_name":"Iulia Cristina Tudor","orcid":"https://orcid.org/0000-0002-4229-2940","observed_orcids":["https://orcid.org/0000-0002-4229-2940"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Iulia Cristina Tudor","raw_affiliation_strings":["Pfizer, Inc., San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer, Inc., San Francisco, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102994771","display_name":"Eric Roland Gauthier","orcid":"https://orcid.org/0000-0002-0160-7571","observed_orcids":["https://orcid.org/0000-0002-0160-7571"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eric Roland Gauthier","raw_affiliation_strings":["Pfizer Inc, San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc, San Francisco, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050035884","display_name":"Akos Gabor Czibere","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Akos Gabor Czibere","raw_affiliation_strings":["Pfizer, Inc., Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer, Inc., Cambridge, MA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014713051","display_name":"Jennifer Keating Litton","orcid":"https://orcid.org/0000-0001-8390-4985","observed_orcids":["https://orcid.org/0000-0001-8390-4985"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer Keating Litton","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5068059897","display_name":"Sara Alsterlind Hurvitz","orcid":"https://orcid.org/0000-0001-7808-7191","observed_orcids":["https://orcid.org/0000-0001-7808-7191"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sara A. Hurvitz","raw_affiliation_strings":["University of California Los Angeles, Los Angeles, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of California Los Angeles, Los Angeles, CA;","institution_ids":["https://openalex.org/I161318765"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":12,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"37","issue":"15_suppl","first_page":"1044","last_page":"1044"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.9878000020980835,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.9878000020980835,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10769","display_name":"BRCA gene mutations in cancer","score":0.011300000362098217,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/talazoparib","display_name":"talazoparib","score":1.0},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.859000027179718},{"id":"https://openalex.org/keywords/her2-negative-breast-cancer","display_name":"HER2-negative breast cancer","score":0.9279999732971191},{"id":"https://openalex.org/keywords/germline-brca1-2-mutation","display_name":"germline BRCA1/2 mutation","score":0.953000009059906},{"id":"https://openalex.org/keywords/locally-advanced-or-metastatic-breast-cancer","display_name":"locally advanced or metastatic breast cancer","score":0.9259999990463257},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9039999842643738},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.9819999933242798},{"id":"https://openalex.org/keywords/clinical-benefit-rate","display_name":"clinical benefit rate","score":0.8830000162124634},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.75},{"id":"https://openalex.org/keywords/hematological-toxicity","display_name":"hematologic toxicity","score":0.6639999747276306},{"id":"https://openalex.org/keywords/american-patients","display_name":"United States patients","score":0.7979999780654907}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8970941305160522},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7109842896461487},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.6719792485237122},{"id":"https://openalex.org/C2776387010","wikidata":"https://www.wikidata.org/wiki/Q408717","display_name":"Eribulin","level":5,"score":0.5948516726493835},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.5716496109962463},{"id":"https://openalex.org/C2780350996","wikidata":"https://www.wikidata.org/wiki/Q420532","display_name":"Vinorelbine","level":4,"score":0.49940061569213867},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.48660314083099365},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.4313561022281647},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4303685128688812},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.35885339975357056},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.13513797521591187},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2019.37.15_suppl.1044","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.1044","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2019.37.15_suppl.1044","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2898158489","https://openalex.org/W3083341170","https://openalex.org/W2898606077","https://openalex.org/W2990201173","https://openalex.org/W3202115015","https://openalex.org/W2807659903","https://openalex.org/W2947169115","https://openalex.org/W2944637757","https://openalex.org/W7162019098","https://openalex.org/W2794023096"],"abstract_inverted_index":{"1044":[0],"Background:":[1],"TALA":[2,32,118,138,156,179,209],"is":[3],"a":[4,113,159,218],"poly(ADP-ribose)":[5],"polymerase":[6],"(PARP)":[7],"inhibitor":[8],"approved":[9],"in":[10,41,51,55,66,116,154,169,177,213],"the":[11,24,56,89,102,117,155,170,178],"US":[12,52,63,103,202],"for":[13],"HER2-":[14,42,205],"g":[15,43,206],"BRCAm":[16,44,207],"LA/MBC.":[17],"Approval":[18],"was":[19],"based":[20],"on":[21],"results":[22],"from":[23,62,101],"Phase":[25],"3":[26],"EMBRACA":[27,67],"trial":[28,223],"comparing":[29],"efficacy/safety":[30],"of":[31,145,152],"(1":[33],"mg/d)":[34],"to":[35],"PCT":[36,149,171,216],"(capecitabine,":[37],"eribulin,":[38],"gemcitabine,":[39],"vinorelbine)":[40],"LA/MBC":[45],"pts.":[46],"This":[47],"analysis":[48],"describes":[49],"outcomes":[50,214],"pts":[53,64,98,153,168,203],"included":[54,181],"pivotal":[57],"study.":[58],"Methods:":[59],"Clinical":[60,222],"findings":[61],"enrolled":[65],"were":[68,87,100,110],"analyzed.":[69],"Pt":[70,108],"characteristics,":[71],"progression-free":[72],"survival":[73],"(PFS),":[74],"objective":[75,161],"response":[76,146,162],"rate":[77,81],"(ORR),":[78],"clinical":[79],"benefit":[80],"(CBR),":[82],"and":[83,134,143,188],"safety/adverse":[84],"events":[85],"(AEs)":[86],"among":[88],"parameters":[90],"assessed.":[91],"Results:":[92],"Of":[93],"431":[94],"randomized":[95],"pts,":[96],"156":[97],"(36%)":[99],"(TALA:":[104],"99;":[105],"PCT:":[106],"57).":[107],"characteristics":[109],"balanced,":[111],"although":[112],"higher":[114],"percentage":[115],"arm":[119,157,180],"had":[120,158],"more":[121,135,195],"poor":[122],"prognostic":[123],"features":[124],"(eg,":[125],"triple-negative":[126],"breast":[127],"cancer,":[128],"disease-free":[129],"interval":[130],"<":[131],"12":[132,165],"mo,":[133],"disease":[136],"sites).":[137],"improved":[139],"PFS,":[140],"ORR,":[141],"CBR,":[142],"duration":[144],"(DOR)":[147],"vs":[148,166,215],"(Table).":[150],"22%":[151],"continued":[160],"at":[163],"month":[164],"0":[167],"arm.":[172],"The":[173],"most":[174],"common":[175],"AEs":[176,193],"anemia,":[182],"neutropenia,":[183],"thrombocytopenia,":[184],"fatigue,":[185],"nausea,":[186],"alopecia,":[187],"headache;":[189],"hematologic":[190],"grade":[191],"3/4":[192],"occurred":[194],"often":[196],"than":[197],"nonhematologic":[198],"AEs.":[199],"Conclusions:":[200],"In":[201],"with":[204,217],"LA/MBC,":[208],"demonstrated":[210],"significant":[211],"improvements":[212],"manageable":[219],"safety":[220],"profile.":[221],"information:":[224],"NCT01945775.":[225],"[Table:":[226],"see":[227],"text]":[228]},"counts_by_year":[{"year":2021,"cited_by_count":1}],"updated_date":"2026-10-17T09:40:24.721904","created_date":"2019-06-07T00:00:00"}